Jhingran P, Davis S M, LaVange L M, Miller D W, Helms R W
Glaxo Wellcome Inc., Research Triangle Park, Durham, North Carolina, USA.
Pharmacoeconomics. 1998 Jun;13(6):707-17. doi: 10.2165/00019053-199813060-00007.
MSQ, the 16-item Migraine-Specific Quality-of-Life Questionnaire (Version 1.0), was developed by Glaxo Wellcome Inc. to assess the effect of migraine and its treatment on patients' health-related quality of life (HR-QOL). The MSQ was hypothesised to measure 3 meaningful dimensions: (i) Role Function-Restrictive; (ii) Role Function-Preventive; and (iii) Emotional Function. The objective of this research was to further investigate the number of dimensions as well as the items contained in each dimension through principal components factor analysis of clinical trial data. Secondary objectives were to determine whether the factor structure changed in post-treatment visits compared with screening visits, to make recommendations for coding the MSQ when the patient did not have a migraine in the previous 4 weeks, and to modify the MSQ if so indicated by this research. Results supported the existence of 3 distinct factors which agreed strongly with the hypothesised dimensions. The analysis of post-treatment data suggested that the underlying factor structure of the MSQ varies as a result of treatment. Based on evaluations of the 'did not have a migraine' response, it was concluded that it be dropped from the MSQ. All these changes have been incorporated into MSQ (Version 2.0) which is being evaluated in studies to determine if its psychometric properties are different than the properties of the previous version.
MSQ，即16项偏头痛特异性生活质量问卷（1.0版），由葛兰素威康公司开发，用于评估偏头痛及其治疗对患者健康相关生活质量（HR-QOL）的影响。MSQ被假设用于测量3个有意义的维度：（i）角色功能-限制性；（ii）角色功能-预防性；以及（iii）情感功能。本研究的目的是通过对临床试验数据进行主成分因子分析，进一步探究维度数量以及每个维度所包含的条目。次要目标是确定与筛查访视相比，治疗后访视时因子结构是否发生变化，为患者在过去4周内未患偏头痛时MSQ的编码提出建议，并根据本研究结果对MSQ进行修改（如有必要）。结果支持存在3个不同的因子，这与假设的维度高度一致。对治疗后数据的分析表明，MSQ的潜在因子结构因治疗而有所不同。基于对“未患偏头痛”回答的评估，得出结论，应从MSQ中删除该选项。所有这些更改已纳入MSQ（2.0版），目前正在研究中进行评估，以确定其心理测量特性是否与先前版本不同。
